Arcus Biosciences (RCUS) Other Accumulated Expenses (2017 - 2026)

Arcus Biosciences' Other Accumulated Expenses history runs 10 years deep, the most recent figure standing at $136.0 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 38.78% year-over-year to $136.0 million; the TTM figure through Mar 2026 stood at $136.0 million (up 38.78% YoY), while the FY2025 annual figure was $154.0 million, up 25.2% from the prior year.
• Other Accumulated Expenses was $136.0 million for Q1 2026 at Arcus Biosciences, down from $154.0 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $154.0 million in Q4 2025 to a low of $2.5 million in Q2 2022.
• Historically, Other Accumulated Expenses has averaged $82.8 million across 5 years, with a median of $76.0 million in 2022.
• Biggest YoY gain for Other Accumulated Expenses was 2535.85% in 2023; the steepest drop was 1.74% in 2023.
• A 5-year view of Other Accumulated Expenses shows it stood at $76.0 million in 2022, then changed by 0.0% to $76.0 million in 2023, then surged by 61.84% to $123.0 million in 2024, then gained by 25.2% to $154.0 million in 2025, then decreased by 11.69% to $136.0 million in 2026.
• The last three Other Accumulated Expenses figures came in at $136.0 million (Q1 2026), $154.0 million (Q4 2025), and $141.0 million (Q3 2025), per Business Quant data.